Skip to main content
. 2015 Jun 19;5:11322. doi: 10.1038/srep11322

Figure 7. TAT-APPsweBBP markedly inhibits APP amyloidogenic processing in 5XFAD mice.

Figure 7

5XFAD mice were euthanized after 8 weeks of treatment, followed by preparation of brain homogenates for biochemical analyses. TAT-APPsweBBP treatment significantly reduced detergent-soluble (A) and insoluble Aβ1−40/42 levels (B), compared to TAT- or PBS-treatments, as assessed by ELISA (*P < 0.05, **P < 0.01, ***P < 0.005, Student’s t test). Data are represented as mean ± SD of Aβ1−40/42 (ng/mg of total protein). (C) In addition, TAT-APPsweBBP reduced total cerebral soluble Aβ (Aβs) and β-CTF, as determined by WB analysis with 6E10, without significantly altering total APP expression. The blot was re-probed with anti-β-actin antibody. (D) Densitometry analysis reveals that TAT-APPsweBBP significantly reduces the band density ratios of β-CTF to holo-APP, compared to TAT- and PBS-treatments (**P < 0.01). Data are represented as mean ± SD.